KRT1 and breast carcinoma: Therefore, we examined whether the effects that we found in TAM-treated breast cancer cells were unique to CSNK1G2. Breast cancer cells were exposed to 2 μM D4476, a CK 1 inhibitor, instead of CSNK1G2 siRNA transfection.